Piperlongumine reduces ovalbumin‑induced asthma and airway inflammation by regulating nuclear factor‑κB activation

Lu,Chun; Zhang,Bing; Xu,Tingting; Zhang,Wenxin; Bai,Bin; Xiao,Zhongxiang; Wu,Liqin; Liang,Guang; Zhang,Yali; Dai,Yuanrong

doi:10.3892/ijmm.2019.4322

Piperlongumine reduces ovalbumin‑induced asthma and airway inflammation by regulating nuclear factor‑κB activation

Authors:
- Chun Lu
- Bing Zhang
- Tingting Xu
- Wenxin Zhang
- Bin Bai
- Zhongxiang Xiao
- Liqin Wu
- Guang Liang
- Yali Zhang
- Yuanrong Dai
View Affiliations

Affiliations: The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, P.R. China, Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, P.R. China
Published online on: August 21, 2019 https://doi.org/10.3892/ijmm.2019.4322
Pages: 1855-1865
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Asthma is a common chronic airway inflammatory disease, characterized by airway inflammation and remodeling. Piperlongumine (PL) has a number of physiological and pharmacological properties. However, the anti‑asthmatic effect of PL has not been reported to date. In the present study, ovalbumin (OVA) was used to sensitize and challenge mice to induce asthma. The results revealed that PL pretreatment reduced OVA‑induced airway inflammatory cell infiltration, reduced Th2 cytokine expression, both in the bronchoalveolar lavage fluid and in lung tissues, reduced the serum IgE level, pro‑inflammatory cytokine [tumor necrosis factor (TNF)‑α and interleukin (IL)‑6] and intercellular adhesion molecule expression, as well as nuclear factor (NF)‑κB activation. In addition, PL also mitigated OVA‑induced goblet cell metaplasia, inhibited mucus protein secretion, mitigated airway fibrosis and downregulated fibrosis marker expression. It was also demonstrated that PL inhibited TNF‑α induced inflammatory cytokine expression and NF‑κB activation in vitro. Taken together, the findings of the present study indicated that PL can reduce OVA‑induced airway inflammation and remodeling in asthmatic mice, and that these effects may be mediated by inhibiting NF‑κB signaling.

View Figures

View References

1	Network GA: The global asthma report 2018. http://www.global-asthmareport.org/.
2	Papi A, Brightling C, Pedersen SE and Reddel HK: Asthma. Lancet. 391:783–800. 2018. View Article : Google Scholar
3	Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR and Kay AB: Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 326:298–304. 1992. View Article : Google Scholar : PubMed/NCBI
4	Kidd P: Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 8:223–246. 2003.PubMed/NCBI
5	Olin JT and Wechsler ME: Asthma: Pathogenesis and novel drugs for treatment. BMJ. 349:pp. g55172014, View Article : Google Scholar : PubMed/NCBI
6	Gray LE and Sly PD: Update in asthma 2017. Am J Respir Crit Care Med. 197:1108–1115. 2018. View Article : Google Scholar : PubMed/NCBI
7	Barnig C, Frossard N and Levy BD: Towards targeting resolution pathways of airway inflammation in asthma. Pharmacol Ther. 186:98–113. 2018. View Article : Google Scholar : PubMed/NCBI
8	Global Initative for Asthma: GINA Report, Global strategy for asthma management and prevention (2015 update). https://ginasthma.org/gina-reports/.
9	Dahl R: Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 100:1307–1317. 2006. View Article : Google Scholar : PubMed/NCBI
10	Roland NJ, Bhalla RK and Earis J: The local side effects of inhaled corticosteroids: Current understanding and review of the literature. Chest. 126:213–219. 2004. View Article : Google Scholar : PubMed/NCBI
11	Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, et al: Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. 125:1237–1244.e2. 2010. View Article : Google Scholar : PubMed/NCBI
12	Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2144–2148. 2000. View Article : Google Scholar
13	Flood-Page PT, Menzies-Gow AN, Kay AB and Robinson DS: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 167:199–204. 2003. View Article : Google Scholar
14	Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER and Costa-Lotufo LV: Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 48:453–463. 2013. View Article : Google Scholar
15	Zou P, Xia Y, Ji J, Chen W, Zhang J, Chen X, Rajamanickam V, Chen G, Wang Z, Chen L, et al: Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. Cancer Lett. 375:114–126. 2016. View Article : Google Scholar : PubMed/NCBI
16	Han JG, Gupta SC, Prasad S and Aggarwal BB: Piperlongumine chemosensitizes tumor cells through interaction with cysteine 179 of IκBα kinase, leading to suppression of NF-κB-regulated gene products. Mol Cancer Ther. 13:2422–2435. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kim N, Do J, Bae JS, Jin HK, Kim JH, Inn KS, Oh MS and Lee JK: Piperlongumine inhibits neuroinflammation via regulating NF-κB signaling pathways in lipopolysaccharide-stimulated BV2 microglia cells. J Pharmacol Sci. 137:195–201. 2018. View Article : Google Scholar : PubMed/NCBI
18	Lee W, Yoo H, Kim JA, Lee S, Jee JG, Lee MY, Lee YM and Bae JS: Barrier protective effects of piperlonguminine in LPS-induced inflammation in vitro and in vivo. Food Chem Toxicol. 58:149–157. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sun J, Xu P, Du X, Zhang Q and Zhu Y: Piperlongumine attenuates collagen-induced arthritis via expansion of myeloid-derived suppressor cells and inhibition of the activation of fibroblast-like synoviocytes. Mol Med Rep. 11:2689–2694. 2015. View Article : Google Scholar
20	Zaynagetdinov R, Ryzhov S, Goldstein AE, Yin H, Novitskiy SV, Goleniewska K, Polosukhin VV, Newcomb DC, Mitchell D, Morschl E, et al: Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice. Am J Respir Cell Mol Biol. 42:564–571. 2010. View Article : Google Scholar :
21	Kim ST, Chun JW, Park G and Koh JW: Comparative quantification of plasma TDRD7 mRNA in cataract patients by real-time polymerase chain reaction. Korean J Ophthalmol. 28:343–350. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ray A and Cohn L: Altering the Th1/Th2 balance as a therapeutic strategy in asthmatic diseases. Curr Opin Investig Drugs. 1:442–448. 2000.
23	Ray A and Cohn L: Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation. J Clin Invest. 104:985–993. 1999. View Article : Google Scholar : PubMed/NCBI
24	Truyen E, Coteur L, Dilissen E, Overbergh L, Dupont LJ, Ceuppens JL and Bullens DM: Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax. 61:202–208. 2006. View Article : Google Scholar : PubMed/NCBI
25	Steinke JW and Borish L: Th2 cytokines and asthma. Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists Respir Res. 2:66–70. 2001.
26	Foster PS, Hogan SP, Ramsay AJ, Matthaei KI and Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyper-reactivity, and lung damage in a mouse asthma model. J Exp Med. 183:195–201. 1996. View Article : Google Scholar : PubMed/NCBI
27	Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL and Donaldson DD: Interleukin-13: Central mediator of allergic asthma. Science. 282:2258–2261. 1998. View Article : Google Scholar : PubMed/NCBI
28	Halwani R, Al-Muhsen S and Hamid Q: Airway remodeling in asthma. Curr Opin Pharmacol. 10:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
29	Yao X, Wang W, Li Y, Lv Z, Guo R, Corrigan CJ, Ding G, Huang K, Sun Y and Ying S: Characteristics of IL-25 and allergen-induced airway fibrosis in a murine model of asthma. Respirology. 20:730–738. 2015. View Article : Google Scholar : PubMed/NCBI
30	An G, Zhang X, Wang W, Huang Q, Li Y, Shan S, Corrigan CJ, Wang W and Ying S: The effects of interleukin-33 on airways collagen deposition and matrix metalloproteinase expression in a murine surrogate of asthma. Immunology 2018 (Epub ahead of print).
31	Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC and Wasserman SI: Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 89:958–967. 1992. View Article : Google Scholar : PubMed/NCBI
32	Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ and Pavord ID: Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 354:697–708. 2006. View Article : Google Scholar : PubMed/NCBI
33	Brown SD, Brown LA, Stephenson S, Dodds JC, Douglas SL, Qu H and Fitzpatrick AM: Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma. J Allergy Clin Immunol. 135:1651–1654. 2015. View Article : Google Scholar : PubMed/NCBI
34	Thomas PS, Yates DH and Barnes PJ: Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 152:76–80. 1995. View Article : Google Scholar : PubMed/NCBI
35	Baeuerle PA and Baichwal VR: NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 65:111–137. 1997. View Article : Google Scholar : PubMed/NCBI
36	Xiao C and Ghosh S: NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol. 560:41–45. 2005. View Article : Google Scholar : PubMed/NCBI
37	Tak PP and Firestein GS: NF-kappaB: A key role in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI
38	Caramori G, Oates T, Nicholson AG, Casolari P, Ito K, Barnes PJ, Papi A, Adcock IM and Chung KF: Activation of NF-kappaB transcription factor in asthma death. Histopathology. 54:507–509. 2009. View Article : Google Scholar : PubMed/NCBI
39	Barnes PJ and Adcock IM: NF-kappa B: A pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci. 18:46–50. 1997. View Article : Google Scholar : PubMed/NCBI
40	Adcock IM, Brown CR, Gelder CM, Shirasaki H, Peters MJ and Barnes PJ: Effects of glucocorticoids on transcription factor activation in human peripheral blood mononuclear cells. Am J Physiol. 268:C331–C338. 1995. View Article : Google Scholar : PubMed/NCBI
41	Ray A and Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA. 91:752–756. 1994. View Article : Google Scholar : PubMed/NCBI
42	Chauhan PS, Singh DK, Dash D and Singh R: Intranasal curcumin regulates chronic asthma in mice by modulating NF-κB activation and MAPK signaling. Phytomedicine. 51:29–38. 2018. View Article : Google Scholar : PubMed/NCBI
43	Gu X, Zhang Q, Du Q, Shen H and Zhu Z: Pinocembrin attenuates allergic airway inflammation via inhibition of NF-κB pathway in mice. Int Immunopharmacol. 53:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
44	Wang TY, Zhou QL, Li M and Shang YX: Shikonin alleviates allergic airway remodeling by inhibiting the ERK-NF-κB signaling pathway. Int Immunopharmacol. 48:169–179. 2017. View Article : Google Scholar : PubMed/NCBI
45	Wang J, Fu Y, Wei Z, He X, Shi M, Kou J, Zhou E, Liu W, Yang Z and Guo C: Anti-asthmatic activity of osthole in an ovalbumin-induced asthma murine model. Respir Physiol Neurobiol. 239:64–69. 2017. View Article : Google Scholar : PubMed/NCBI
46	Li J, Luo L, Wang X, Liao B and Li G: Inhibition of NF-kappaB expression and allergen-induced airway inflammation in a mouse allergic asthma model by andrographolide. Cell Mol Immunol. 6:381–385. 2009. View Article : Google Scholar : PubMed/NCBI